Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reboxetine and Citalopram for Negative Symptoms of Schizophrenia
NCT01300364Phase 4Unknown
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Nov 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of reboxetine and citalopram in schizophrenia, sponsored by Fundació Sant Joan de Déu. Status: unknown.
02
Drugs
reboxetinecitalopram
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01300364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300364.